Literature DB >> 15736303

Prognostic value of chronic obstructive pulmonary disease in 2994 cases of lung cancer.

Angel López-Encuentra1, Julio Astudillo, Jorge Cerezal, Federico Gonzalez-Aragoneses, Nuria Novoa, Abel Sánchez-Palencia.   

Abstract

OBJECTIVE: Given the frequent association between chronic obstructive pulmonary disease (COPD) and lung cancer (LC), the objective of this paper is to analyse the prognosis of this comorbidity.
METHODS: Multicenter prospective study compiling 2994 consecutive cases of surgically treated LC (1993-1997), the population with non-small cell lung cancer and complete resection was selected for the prognostic study of COPD. COPD is defined when the FEV1/FVC is <0.7 (n=1370; 46%). Overall and conditional survivals (survival likelihood when alive at 2, 3 or 5 years after treatment) as well as the degree of severity (FEV1% percentiles) were calculated to establish prognosis.
RESULTS: Although the overall survival is similar whether or not COPD is present (Log-rank: 0.34), the conditional survival analysis is different in every stage at 60 months (Log-rank: 0.02) and different in stage pI at 24-36 months (Log-rank: 0.04). In LC (stage pI) with COPD, the presence of a worst pulmonary function (last FEV1% percentile vs first FEV1% percentile) is a bad prognostic factor (Log-rank: 0.002).
CONCLUSIONS: The analysis of conditional survival at 24 months shows that COPD can be considered as a prognostic factor and that there is a clear relationship between the severity of the condition (FEV1%) and survival.

Entities:  

Mesh:

Year:  2005        PMID: 15736303     DOI: 10.1016/j.ejcts.2004.09.010

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  17 in total

Review 1.  Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.

Authors:  Mathew Suji Eapen; Philip M Hansbro; Anna-Karin Larsson-Callerfelt; Mohit K Jolly; Stephen Myers; Pawan Sharma; Bernadette Jones; Md Atiqur Rahman; James Markos; Collin Chia; Josie Larby; Greg Haug; Ashutosh Hardikar; Heinrich C Weber; George Mabeza; Vinicius Cavalheri; Yet H Khor; Christine F McDonald; Sukhwinder Singh Sohal
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

Review 2.  Bacterial Pneumonia in Patients with Cancer: Novel Risk Factors and Management.

Authors:  Justin L Wong; Scott E Evans
Journal:  Clin Chest Med       Date:  2017-03-01       Impact factor: 2.878

3.  The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection.

Authors:  Rihong Zhai; Xiaojin Yu; Andrea Shafer; John C Wain; David C Christiani
Journal:  Chest       Date:  2014-02       Impact factor: 9.410

4.  Previous tumour as a prognostic factor in stage I non-small cell lung cancer.

Authors:  Angel López-Encuentra; Agustín Gómez de la Cámara; Ramón Rami-Porta; José Luis Duque-Medina; José Luis Martín de Nicolás; Javier Sayas
Journal:  Thorax       Date:  2006-01-31       Impact factor: 9.139

5.  The effect of different comorbidities on survival of non-small cells lung cancer patients.

Authors:  Maria Iachina; Erik Jakobsen; Henrik Møller; Margreet Lüchtenborg; Anders Mellemgaard; Mark Krasnik; Anders Green
Journal:  Lung       Date:  2014-12-17       Impact factor: 2.584

6.  Long-acting muscarinic antagonist and long-acting β2-agonist therapy to optimize chronic obstructive pulmonary disease prior to lung cancer surgery.

Authors:  Takashi Makino; Hajime Otsuka; Yoshinobu Hata; Satoshi Koezuka; Yoko Azuma; Kazutoshi Isobe; Keishi Sugino; Satoru Ebihara; Sakae Homma; Akira Iyoda
Journal:  Mol Clin Oncol       Date:  2018-03-26

7.  Prognosis of smokers following resection of pathological stage I non-small-cell lung carcinoma.

Authors:  Noriyoshi Sawabata; Shinichiro Miyoshi; Akihide Matsumura; Mitsunori Ohta; Hajime Maeda; Hirofumi Sueki; Masanobu Hayakawa; Meinoshin Okumura; Yoshiki Sawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2007-10

8.  Impact of COPD in patients with lung cancer and advanced disease treated with chemotherapy and/or tyrosine kinase inhibitors.

Authors:  José Luis Izquierdo; Pilar Resano; Abdulkader El Hachem; Desiré Graziani; Carlos Almonacid; Ignacio M Sánchez
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-09-30

9.  Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations.

Authors:  Jeong Uk Lim; Chang Dong Yeo; Chin Kook Rhee; Yong Hyun Kim; Chan Kwon Park; Ju Sang Kim; Jin Woo Kim; Sang Haak Lee; Seung Joon Kim; Hyoung Kyu Yoon; Tae-Jung Kim; Kyo Young Lee
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

10.  Clinical impact of prevalence and severity of COPD on the decision-making process for therapeutic management of lung cancer patients.

Authors:  Naozumi Hashimoto; Asuka Matsuzaki; Yu Okada; Naoyuki Imai; Shingo Iwano; Kenji Wakai; Kazuyoshi Imaizumi; Kohei Yokoi; Yoshinori Hasegawa
Journal:  BMC Pulm Med       Date:  2014-02-05       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.